Anavex Life Sciences to Present at the 5th Annual Mental Health Parity Addiction Equity Act Business Roundtable in Washington...
November 08 2017 - 06:00AM
Anavex Life Sciences Corp. (Anavex or the Company) (Nasdaq:AVXL), a
clinical-stage biopharmaceutical company developing differentiated
therapeutics for the treatment of neurodegenerative and
neurodevelopmental diseases including Alzheimer’s disease, other
central nervous system (CNS) diseases, pain and various types of
cancer, today announced that Christopher U. Missling, PhD,
President and Chief Executive Officer of Anavex, will be a panelist
at the 5th Annual Mental Health Parity and Addiction Equity Act
(MHPAEA) Business Roundtable. The event is taking place on
Wednesday, November 8, 2017, at the United States Capitol Visitor
Center, in Washington, DC.
The panel will discuss the latest challenges
surrounding the advancement of therapies for the treatment of
Post-Traumatic Stress Disorder (PTSD), Traumatic Brain Injury
(TBI), and Alzheimer’s disease since the MHPAEA of 2008 was
implemented. The panelists will also evaluate the progress made
since the 21st Century Cures Act, which was passed last year with
modernization steps for the Food and Drug Administration (FDA),
along with additional parity elements for the mental healthcare
system and resources for precision medicine and biomedical
research.
“Mental health is an issue our nation must
address, and the best way to do that is to continue to work
together from all sides and educate our policy leaders,” said E.
Teresa Touey, organizer of the MHPAEA Business Roundtable. “It is
important for panelists such as Dr. Missling to attend in order to
lend his expertise in developing therapies for diseases such as
Alzheimer’s disease as well as other neurological disorders with
high unmet needs.”
About the Mental Health Parity and
Addiction Equity Act (MHPAEA)The Mental Health Parity and
Addiction Equity Act of 2008 (MHPAEA) requires group health plans
and health insurance issuers to ensure that financial requirements
(such as co-pays, deductibles) and treatment limitations (such as
visit limits) applicable to mental health or substance use disorder
(MH/SUD) benefits are no more restrictive than the predominant
requirements or limitations applied to substantially all
medical/surgical benefits. MHPAEA supplements prior provisions
under the Mental Health Parity Act of 1996 (MHPA), which
required parity with respect to aggregate lifetime and annual
dollar limits for mental health benefits.
About Anavex Life Sciences
Corp.Anavex Life Sciences Corp. (Nasdaq: AVXL) is a
publicly traded biopharmaceutical company dedicated to the
development of differentiated therapeutics for the treatment of
neurodegenerative and neurodevelopmental diseases including
Alzheimer’s disease, other central nervous system (CNS) diseases,
pain and various types of cancer. Anavex’s lead drug candidate,
ANAVEX®2-73, recently completed a successful a Phase 2a clinical
trial for Alzheimer’s disease. ANAVEX®2-73 is an orally available
drug candidate that restores cellular homeostasis by targeting
sigma-1 and muscarinic receptors. Preclinical studies demonstrated
its potential to halt and/or reverse the course of Alzheimer’s
disease. It has also exhibited anticonvulsant, anti-amnesic,
neuroprotective and anti-depressant properties in animal models,
indicating its potential to treat additional CNS disorders,
including epilepsy. The Michael J. Fox Foundation for Parkinson’s
Research has awarded Anavex a research grant to develop ANAVEX®2-73
for the treatment of Parkinson’s disease. The grant fully funds a
preclinical study, which could justify moving ANAVEX®2-73 into a
Parkinson’s disease clinical trial. ANAVEX®3-71, also targeting
sigma-1 and M1 muscarinic receptors, is a promising preclinical
drug candidate demonstrating disease modifications against the
major Alzheimer’s hallmarks in transgenic (3xTg-AD) mice, including
cognitive deficits, amyloid and tau pathologies, and also with
beneficial effects on neuroinflammation and mitochondrial
dysfunctions. Further information is available
at www.anavex.com. You can also connect with the company
on Twitter, Facebook and LinkedIn.
Forward-Looking
StatementsStatements in this press release that are not
strictly historical in nature are forward-looking statements. These
statements are only predictions based on current information and
expectations and involve a number of risks and uncertainties.
Actual events or results may differ materially from those projected
in any of such statements due to various factors, including the
risks set forth in the Company’s most recent Annual Report on Form
10-K filed with the SEC. Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of the date hereof. All forward-looking statements are qualified in
their entirety by this cautionary statement and Anavex Life
Sciences Corp. undertakes no obligation to revise or update this
press release to reflect events or circumstances after the date
hereof.
For Further Information:Anavex
Life Sciences Corp.Research & Business DevelopmentToll-free:
1-844-689-3939Email: info@anavex.com
Investors & Media:Clayton RobertsonThe
Trout Group(646) 378-2900crobertson@troutgroup.com
Anavex Life Sciences (NASDAQ:AVXL)
Historical Stock Chart
From Feb 2024 to Mar 2024
Anavex Life Sciences (NASDAQ:AVXL)
Historical Stock Chart
From Mar 2023 to Mar 2024